This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

User Evaluation of the MiniMed 620G and 640G Insulin Pumps

This study has been completed.
Information provided by (Responsible Party):
Medtronic Diabetes Identifier:
First received: November 8, 2012
Last updated: March 17, 2016
Last verified: March 2016

This six center international study will include two United Kingdom National Health Service centers, two centers in Melbourne, Australia and one center each in Denmark and Spain. The objective of the study is to evaluate subject acceptance of the a new insulin pump and transmitter together with the accompanying training materials. Descriptive data from participant questionnaires and device uploads will be evaluated.

Pediatric subjects between the ages of 7 - 18 years and adults from the age of 19 years of age upwards, who currently use an insulin pump in the management of their type 1 or type 2 diabetes, will be invited to participate. Each subject will be trained on the study device and then use it for approximately six weeks. During this time there will be three in-clinic visits and four follow-up phone calls, scheduled at the subjects' convenience. At the end of this period, they will revert back to their original insulin pump and complete a questionnaire on the study pump training materials, features and usability.

Condition Intervention
Type 1 Diabetes Type 2 Diabetes Device: Medtronic MiniMed 620G or 640G Insulin Pump

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A User Evaluation of the MiniMed® 620G and 640G Insulin Pumps and Guardian® Link Transmitter

Resource links provided by NLM:

Further study details as provided by Medtronic Diabetes:

Primary Outcome Measures:
  • User Acceptance of the New MiniMed 620G and 640G Insulin Pumps and Guardian Link Transmitter [ Time Frame: Four weeks of pump wear ]
    Descriptive summary will be used to characterize the results of the study questionnaires. The questionnaire will use a Likert scale (rating of 1 to 7) to assess overall subject acceptance of the MiniMed 620G, 640G, and Guardian Link Transmitter. A response of 4 or greater on the Likert scale will be considered positive and indicate and product acceptance.

Enrollment: 55
Study Start Date: March 2013
Study Completion Date: December 2014
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Insulin dependent diabetics
Subjects currently using an insulin pump transferred to use the Medtronic MiniMed 620G and 640G insulin pumps and Guardian Link transmitter
Device: Medtronic MiniMed 620G or 640G Insulin Pump
Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.


Ages Eligible for Study:   7 Years to 99 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is 7 years or older at time of screening
  • Subject is current insulin pump user for at least 3 months
  • Subject has the following Continuous Glucose Monitoring experience as determined by the Investigator:

    • Has experience and is able to insert/change sensor by herself/himself and
    • Has experience and can recharge the transmitter and
    • Has experience and can read sensor data in real-time on her/his pump screen
  • Subject has signed a Patient Informed Consent form and is willing to comply with the study procedures;
  • Subject is willing to complete study questionnaires throughout the study
  • Must have one of the following clinical diagnosis:

    • Type 1 diabetes, for a minimum of 6 months prior to enrollment
    • Insulin requiring type 2 diabetes, for a minimum of 6 months prior to enrollment

Exclusion Criteria:

  • Female subject has a positive urine pregnancy screening test.
  • Female subject who plans to become pregnant during the course of study. If a woman becomes pregnant during participation, she will be withdrawn
  • Subject has any condition that, in the opinion of the Investigator or qualified Investigational Center staff, may preclude him/her from participating in the study and completing study related procedures.
  • Subject has impaired vision or hearing problems that could compromise the handling of the device as determined by Investigator or qualified Investigational Center staff
  • Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01726621

St Vincent Hospital and The University of Melbourne
Fitzroy, Australia, 3065
The Royal Melbourne Hospital
Patkville, Australia, 3050
Herlev Hospital
Herlev, Denmark
Barcelona University Hospital
Barcelona, Spain, 08036
United Kingdom
University College Hospital
London, United Kingdom, NW1 2PG
King's College London
London, United Kingdom, SE5 9NU
Sponsors and Collaborators
Medtronic Diabetes
Principal Investigator: Pratik Choudhary, MBBS, MRCP King's College London
  More Information

Responsible Party: Medtronic Diabetes Identifier: NCT01726621     History of Changes
Other Study ID Numbers: CEP267
Study First Received: November 8, 2012
Results First Received: July 2, 2015
Last Updated: March 17, 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on July 21, 2017